567 related articles for article (PubMed ID: 10702886)
1. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A inhibition on the metabolism of cilostazol.
Suri A; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888
[TBL] [Abstract][Full Text] [Related]
3. Effect of omeprazole on the metabolism of cilostazol.
Suri A; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():53-9. PubMed ID: 10702887
[TBL] [Abstract][Full Text] [Related]
4. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Bramer SL; Forbes WP; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
[TBL] [Abstract][Full Text] [Related]
6. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers.
Bramer SL; Brisson J; Corey AE; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():69-77. PubMed ID: 10702889
[TBL] [Abstract][Full Text] [Related]
7. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
[TBL] [Abstract][Full Text] [Related]
9. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
11. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
13. Interaction potential and tolerability of the coadministration of cilostazol and aspirin.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():87-93. PubMed ID: 10702891
[TBL] [Abstract][Full Text] [Related]
14. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
15. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.
Johnson JA; Burlew BS
Drug Metab Dispos; 1996 Mar; 24(3):350-5. PubMed ID: 8820427
[TBL] [Abstract][Full Text] [Related]
16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
17. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.
Mallikaarjun S; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():79-86. PubMed ID: 10702890
[TBL] [Abstract][Full Text] [Related]
18. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
[TBL] [Abstract][Full Text] [Related]
19. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers.
Kim KP; Kim BH; Lim KS; Kim TE; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2098-106. PubMed ID: 19922880
[TBL] [Abstract][Full Text] [Related]
20. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
